Pulmonx Corporation (LUNG) Reports In-Line Q1 EPS; Offers FY23 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Pulmonx Corporation (LUNG) Reports In-Line Q1 EPS; Offers FY23 Revenue Guidance

Pulmonx Reports First Quarter 2023 Financial Results

May 2, 2023 4:05 PM EDT

REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2023 ended March 31, 2023.

Recent Highlights

Recorded worldwide revenue of $14.5 million in the first quarter of 2023, a 35% increase over the same period last year and an increase of 37% on a constant currency basisDelivered $9.3 million in U.S. revenue in the first quarter of 2023, representing 55% year-over-year growthRealized gross margin of 73% in... More